The Precision Medicine in Diabetes Initiative (PMDI) is a joint effort of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). The PMDI recently published a Consensus Report jointly in Diabetes Care and Diabetologia ( https://pubmed.ncbi.nlm.nih.gov/32561617 and https://pubmed.ncbi.nlm.nih.gov/32556613 )
This report provides an evaluation of the current state of precision medicine as applied to diabetes (diagnostics, therapeutics, prevention, prognosis), key barriers and opportunities, as well as prospects for the future. Forms of diabetes where precision diagnosis is currently feasible and effective (i.e., monogenic forms) are presented, while the major hurdles to the global implementation of precision diagnosis of complex forms of diabetes were discussed; similar content focused on precision therapeutics.
A series of evidence-based reviews are ongoing and will provide a roadmap for precision medicine in diabetes that helps improve the quality of life for all those with diabetes.
Program - First ADA International Symposium on Precision Medicine, October 2019